MYCOLab Ai Logo - gold and army green

Study protocol for ‘Psilocybin in patients with fibromyalgia: brain biomarkers of action’

Summary

Researchers are testing whether psilocybin (the active compound in magic mushrooms) combined with therapeutic support can help people with fibromyalgia, a chronic pain condition. The study will measure brain activity using EEG and brain imaging to understand how psilocybin might reduce pain and improve mental health. Twenty patients will receive guided psilocybin sessions over eight weeks while researchers track changes in brain function and pain levels.

Background

Fibromyalgia is a debilitating form of chronic widespread pain that remains poorly understood with limited treatment options. Current therapies show only moderate efficacy and often fail to address comorbid mental health symptoms. Recent clinical psychedelic research suggests potential therapeutic benefits for various conditions including depression, anxiety, and chronic pain.

Objective

This study investigates the central mechanisms of psilocybin-assisted therapy in fibromyalgia patients, with primary focus on brain biomarkers captured through EEG recordings during acute psychedelic states and pre/post MRI imaging. The study aims to establish neurophysiological markers of therapeutic action and inform future clinical trials.

Results

This is a study protocol paper, not a results paper. Data collection and analysis are ongoing. Results are not yet available.

Conclusion

This mechanistic study will provide valuable insights into brain mechanisms underlying psilocybin-assisted therapy for fibromyalgia with implications for broader psychedelic therapeutic applications. Results will inform design of future randomized controlled trials and advance understanding of psychedelic mechanisms in chronic pain conditions.
  • Published in:Frontiers in Psychiatry,
  • Study Type:Study Protocol, Clinical Trial,
  • Source: PMID: 38983371, DOI: 10.3389/fpsyt.2024.1320780
Scroll to Top